GEN Exclusives

More »

GEN News Highlights

More »
Jul 30, 2009

SeqWright and Lilly to Sequence Genomic Regions Associated with Psychiatric Diseases Using Roche Technologies

  • Roche Applied Science will supply Eli Lilly and SeqWright with technologies to identify genetic variants associated with various psychiatric diseases. SeqWright will utilize NimbleGen sequence capture technology to selectively enrich approximately 40 megabases of the human genome. This will then be sequenced using 454 Life Sciences’ Genome Sequencer FLX System.

    “Just a year ago, it would have been impossible to imagine how we could selectively sequence such a large portion of the human genome in such a fast and cost-effective manner,” remarks Brian Edmonds, Ph.D., research advisor, global external research and development, Eli Lilly.  “Our goal at Lilly is to improve the outcomes of individual patients; increasing the speed at which we begin to understand the basis of disease is critical to improving those outcomes. We are participating in this collaboration as a way to better examine the root causes of various psychiatric diseases.”

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »